ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1515

Accounting for Rheumatoid Arthritis in the Determination of 10 Year Cardiovascular Risk

Rupal Chavda and Rochella A. Ostrowski, Rheumatology, Loyola University Medical Center, Maywood, IL

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease, rheumatoid arthritis (RA) and risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Patients with rheumatoid arthritis (RA) carry a higher risk
for cardiovascular disease (CVD) independent of traditional risk factors.  In
this study, we set out to determine the proportion of patients in our practice
who receive cholesterol screening, and we evaluated the effects of the EULAR
(European League Against Rheumatism) risk multiplication factor1 on the
number of RA patients identified as having a high or moderate 10 year risk for
CVD.   

Methods:

A chart review was performed for adult RA patients evaluated
as return visits in the division of Rheumatology at our institution from June
1, 2012 to June 1, 2013.  Clinical information was reviewed for CVD or CVD risk
equivalents (cerebrovascular accident, peripheral artery disease, diabetes
mellitus).  The Framingham 10 year risk for CVD was calculated for patients who
did not have CVD or CVD risk equivalents.  A risk multiplier of 1.5 recommended
by the EULAR for patients with 2 risk factors (disease duration > 10 years, seropositivity,
or severe extra-articular manifestations) was applied.  We evaluated the
proportion of patients who received cholesterol screening and the proportion of
patients taking statin therapy as indicated by the 10 year risk, for CVD, with
and without the EULAR risk multiplication factor.

Results:

Of 520 patients who met inclusion criteria, 364 (70% , 95%CI
66.0-73.9%) received cholesterol screening.  The proportion of patients with ≥2
CVD risk factors who had high or moderate risk (>20% or 10-20% 10 year risk
respectively) increased from 12.5% to 20% when the EULAR risk multiplication
factor was applied (Table 1).  Amongst patients with any number of risk factors,
the proportion of patients with high or moderate risk increased from 10.3% to
14.6% (Table 2).   Of 16 patients with ≥2 risk factors who were not at target
for low density lipoprotein (LDL) levels, 11 were not receiving statin
therapy.  In the larger patient cohort, 31 patients were not at LDL goal, and
23 of these were not on statin therapy.

Conclusion:

Given the increased risk for CVD in RA patients, methods to
increase the rate of cholesterol screening should be explored.  Additionally,
the EULAR multiplication factor serves as a valuable tool when determining the 10
year risk for CVD in RA patients who otherwise may not be identified as
requiring lipid lowering therapy.

References:

1.       Peters
MJL et al.  EULAR evidence-based recommendations for cardiovascular risk
management in patients with rheumatoid arthritis and other forms of inflammatory
arthritis.  Ann Rheum Dis 2010;69:325-31.


Disclosure: R. Chavda, None; R. A. Ostrowski, None.

To cite this abstract in AMA style:

Chavda R, Ostrowski RA. Accounting for Rheumatoid Arthritis in the Determination of 10 Year Cardiovascular Risk [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/accounting-for-rheumatoid-arthritis-in-the-determination-of-10-year-cardiovascular-risk/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/accounting-for-rheumatoid-arthritis-in-the-determination-of-10-year-cardiovascular-risk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology